Physician profile
Adarsh Sidda
NPI 1346602505
$3,090.64
in general payments reported to CMS, 2019-2025
34 companies · $1,289 in 2025
The $1,289 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $85.85 · 2023: $481 · 2024: $1,235 · 2025: $1,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,651 · Long Term Medical Supply Or Device Loan: $1,296 · Education: $58.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,650.59 |
| Long Term Medical Supply Or Device Loan | $1,296.10 |
| Education | $58.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,462.19 | 2022-2025 | |
| Pfizer INC. | $185.98 | 2023-2025 | |
| Incyte Corporation | $135.88 | 2022-2024 | Jakafi, Monjuvi, Pemazyre |
| Astrazeneca Pharmaceuticals Lp | $97.30 | 2023-2025 | Enhertu, Calquence, Imfinzi |
| Merck Sharp & Dohme LLC | $95.97 | 2023-2025 | Keytruda, Keytruda Qlex |
| Abbvie INC. | $89.01 | 2024-2025 | |
| Stemline Therapeutics INC. | $85.30 | 2024-2025 | Orserdu |
| E.R. Squibb & Sons, L.L.C. | $80.14 | 2024-2025 | Opdivo |
| Inari Medical, INC. | $65.85 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Genzyme Corporation | $62.34 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.09 | 2024-2025 | Fruzaqla |
| Astellas Pharma US INC | $49.67 | 2024-2025 | Vyloy, Xospata |
| Sobi, INC | $46.87 | 2023-2025 | |
| Tempus Ai, INC | $43.31 | 2024 | |
| Exelixis INC. | $42.97 | 2023 | Cabometyx |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $38.24 | 2022-2023 | Lumakras |
| Medtronic, INC. | $32.37 | 2024 | Osteocool Rf Ablation System |
| Bayer Healthcare Pharmaceuticals INC. | $32.26 | 2023-2025 | |
| Springworks Therapeutics, INC. | $29.39 | 2025 | Ogsiveo |
| Adc Therapeutics America, INC. | $29.13 | 2024 | |
| Gilead Sciences, INC. | $29.04 | 2025 | Trodelvy |
| Pharmaessentia USA Corporation | $28.83 | 2023 | Besremi |
| Emd Serono, INC. | $28.30 | 2025 | |
| Daiichi Sankyo INC. | $27.69 | 2023 | Enhertu |
| Beone Medicines USA, INC. | $26.91 | 2025 | Brukinsa |
| G1 Therapeutics, INC. | $25.44 | 2023 | Cosela |
| Eisai INC. | $25.34 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $24.11 | 2023 | Onivyde |
| Cti Biopharma Corp. | $23.79 | 2022 | |
| Celgene Corporation | $19.67 | 2025 | Reblozyl |
| Aveo Pharmaceuticals, INC. | $19.31 | 2024 | |
| Janssen Biotech, INC. | $18.61 | 2025 | Tecvayli, Talvey |
| Lilly USA, LLC | $16.14 | 2025 | Jaypirca, Verzenio |
| Array Biopharma INC | $12.20 | 2025 | Mektovi, Braftovi, Xalkori |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adarsh Sidda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.